SYSTEMATIC REVIEW article
Front. Pharmacol.
Sec. Ethnopharmacology
This article is part of the Research TopicImmunomodulatory Natural Products - Their Pharmacological and Therapeutic PotentialView all 21 articles
Synergistic Antitumor Effects of Astragalus Polysaccharides: A Preclinical Systematic Review and Meta-Analysis
Provisionally accepted
- 1Chengdu University of Chinese Medicine, Cheng Du, China
- 2Sichuan Cancer Hospital and Institute, Chengdu, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Accumulating evidence suggests that astragalus polysaccharide (APS) may enhance the efficacy of conventional cancer therapies through multiple mechanisms. However, the synergistic effects of APS have not been systematically quantified. This meta-analysis was therefore conducted to quantify these potential synergistic antitumor effects and provide preclinical evidence to inform future clinical trials. Methods: Following PRISMA 2020 guidelines, we systematically searched ten databases (including PubMed and Web of Science) for preclinical studies from inception to May 2025 using predefined inclusion criteria. Risk of bias was assessed using SYRCLE's RoB tool. Meta-analyses and subgroup analyses were performed using RevMan 5.4.1, while publication bias was assessed via funnel plots and Egger's test (Stata 17.0). This systematic review was prospectively registered in PROSPERO (registration number: CRD420251047751). Results: Forty-one publications (44 independent studies) involving 748 animals were included. APS combination therapy was associated with significant improvements in tumor-related outcomes, including reduced tumor weight and volume, suppressed metastasis, and prolonged survival. Mechanistically, APS co-administration enhanced CD8⁺ T-cell infiltration, increased splenic and thymic indices, modulated cytokine profiles (TNF-α, IL-2, IFN-γ, IL-12, IL-6, IL-10), and reduced PD-1/PD-L1 expression in tumor tissue. Additionally, APS appeared to alleviate chemotherapy-induced nephrotoxicity, as evidenced by lower serum creatinine levels. Subgroup analyses indicated that heterogeneity was partially explained by model type, APS dosing regimen, and combination therapy modality. The certainty of evidence for primary outcomes was rated as low or very low according to the GRADE assessment. Conclusion: This meta-analysis provides preclinical evidence that APS may serve as an adjunctive agent to enhance the efficacy of conventional cancer therapies. However, given the low certainty of current evidence, further mechanistic studies and well-designed clinical trials are urgently warranted to establish its efficacy and therapeutic role in oncology.
Keywords: Astragalus polysaccharide, preclinical studies, antitumor, Meta-analysis, Traditional Chinese Medicine
Received: 24 Jul 2025; Accepted: 28 Nov 2025.
Copyright: © 2025 Zhang, Yang, Chen, Huang and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Jianming Huang
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.